Epilepsy News and Research

Latest Epilepsy News and Research

Embryos with two mums to remove the risk of hereditary diseases: new research

New research published in the journal Nature, could pave the way to world’s first genetically modified human baby. The research involves making embryos with genes from one man and two women. There are hundreds or families around the world who are left childless or have serious ill babies because they carry genes for hereditary illnesses. This research may bring hope to such couples. According to scientists on the team, within the next three years these women will be able to avail such techniques. There has been skepticism regarding ethical issues attached to making of “designer babies”.

16 Apr 2010

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Vertex Pharmaceuticals Incorporated today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity.

16 Apr 2010

Problems faced by epileptic patients

Physicians treating patients with epilepsy are in a difficult legal situation when they have to assess their patients' ability to drive. In the current edition of the Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[13]: 217-23), the occupational physician Monika Gube and her coauthors describe the problems, using an individual case as an example.

16 Apr 2010

Study combines CT and VBM to provide accurate picture of autistic brain

A new study, the first of its kind, combines two complementary analytical brain imaging techniques, to provide a more comprehensive and accurate picture of the neuroanatomy of the autistic brain. The study, published in the April issue of neuroimaging journal Human Brain Mapping, was conducted by researchers at The Montreal Neurological Institute and Hospital - The Neuro, McGill University and the Universit- de Montr-al.

15 Apr 2010

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a definitive Clinical Trial Agreement (CTA) with the National Institute on Drug Abuse (NIDA) to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. As part of the CTA, NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the estimated $10 million trial cost.

15 Apr 2010

2010 UCBeyond Scholarship Program launched to help students living with chronic illnesses

UCB Canada Inc. is proud to announce the launch of the 2010 UCBeyond Scholarship Program. During its four-year lifespan, the UCBeyond Scholarship has allocated almost 70 educational bursaries worth close to $350,000.00 CAN to students living with chronic illnesses such as rheumatoid arthritis, Crohn's disease and epilepsy.

15 Apr 2010

Epilepsy patients who take Ginkgo products face increased risk of seizures: Report

Restrictions should be placed on the use of Ginkgo biloba - a top-selling herbal remedy - because of growing scientific evidence that Ginkgo may increase the risk of seizures in people with epilepsy and could reduce the effectiveness of anti-seizure drugs, a new report concludes. The article appears in ACS' monthly Journal of Natural Products.

15 Apr 2010

Anticonvulsants increase suicide risk

Dr. Elisabetta Patorno, a research fellow at Brigham and Women's Hospital and Harvard Medical School in Boston has published a study this week in the Journal of American Medical Association which found that taking anticonvulsant drugs raise thoughts of suicide and risks of actually trying to commit suicide by two times the norm. The study was sponsored by the Harvard School of Public Health and HealthCore, a research subsidiary of WellPoint. WellPoint is a health benefits company that serves the Blue Cross Blue Shield network.

14 Apr 2010

First direct recording of mirror neurons in the brain

Mirror neurons, many say, are what make us human. They are the cells in the brain that fire not only when we perform a particular action but also when we watch someone else perform that same action.

13 Apr 2010

New patient education video and guidebook for MS patients

Silver screen star Teri Garr is the host of the American Academy of Neurology Foundation's newest patient education video and guidebook, Living Well: A Guide to Managing Multiple Sclerosis for Patients and Families.

12 Apr 2010

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

The antiepileptic drug Vimpat- (lacosamide) (C-V) will be the subject of numerous studies and analyses-both UCB-sponsored and independent-at the 62nd annual American Academy of Neurology meeting, taking place at the Metro Toronto Convention Centre in Toronto from April 10-17.

9 Apr 2010

Catalyst Pharmaceutical Partners' vigabatrin data to be presented at 41st ASAM conference

Catalyst Pharmaceutical Partners, Inc. today announced that on Friday April 16th, Eugene C. Somoza, MD, PhD, University of Cincinnati College of Medicine and VA Medical Center, Cincinnati, OH will present a paper he authored along with Charles Gorodetzky, MD, PhD, Douglas Winship and Peggy Somoza, entitled: "A Multi-Site, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Vigabatrin (VGB) for Treating Cocaine Dependence"

9 Apr 2010

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

In a clinical trial known as PROVE 3 published in this week's New England Journal of Medicine, treatment with telaprevir-based regimens significantly increased rates of sustained viral response (SVR) in patients with genotype 1 hepatitis C virus (HCV) infection who did not achieve SVR with at least one prior course of pegylated-interferon and ribavirin therapy.

8 Apr 2010

Smoking may increase risk of MS in people who have established risk factors for MS

A new study shows that smoking may increase the risk of multiple sclerosis in people who also have specific established risk factors for MS. The research is found in the April 7, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

8 Apr 2010

Children with FASD show high prevalence of developing epilepsy

Children with Fetal Alcohol Spectrum Disorder show a very high prevalence of developing epilepsy and having seizures, according to a national study by Queen's University researchers.

7 Apr 2010

USPTO issues patent for Taro Pharmaceutical Industries' T2007

Taro Pharmaceutical Industries Ltd. announced that the U.S. Patent and Trademark Office has issued United States Patent No. 7,683,071 covering T2007. The patent, entitled "Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid," is for one of a class of non-sedating barbiturate compounds currently in development by the Company.

6 Apr 2010

Strong demand leads to 5.1% growth in 2009 U.S. sales of ethical pharmaceuticals

IMS Health today reported 5.1 percent growth in 2009 U.S. sales of ethical pharmaceuticals and insulins through retail and non-retail channels, reaching $300.3 billion, compared with growth of 1.8 percent in 2008.

2 Apr 2010

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended December 31, 2009.

1 Apr 2010

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.

31 Mar 2010

PhRMA report: 234 medicines in development for special health care needs of children

America's pharmaceutical research and biotechnology companies are developing 234 medicines for the special health care needs of children, according to a new report released today by the Pharmaceutical Research and Manufacturers of America.

31 Mar 2010

Epilepsy News and Research

Latest Epilepsy News and Research

Embryos with two mums to remove the risk of hereditary diseases: new research

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

Problems faced by epileptic patients

Study combines CT and VBM to provide accurate picture of autistic brain

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

2010 UCBeyond Scholarship Program launched to help students living with chronic illnesses

Epilepsy patients who take Ginkgo products face increased risk of seizures: Report

Anticonvulsants increase suicide risk

First direct recording of mirror neurons in the brain

New patient education video and guidebook for MS patients

AED Vimpat to be the subject of numerous studies and analyses at AAN meeting

Catalyst Pharmaceutical Partners' vigabatrin data to be presented at 41st ASAM conference

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

Smoking may increase risk of MS in people who have established risk factors for MS

Children with FASD show high prevalence of developing epilepsy

USPTO issues patent for Taro Pharmaceutical Industries' T2007

Strong demand leads to 5.1% growth in 2009 U.S. sales of ethical pharmaceuticals

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

PhRMA report: 234 medicines in development for special health care needs of children

Fast Facts - Everything there is to know about epilepsy eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Epilepsy News and Research

Latest Epilepsy News and Research

Fast Facts - Everything there is to know about epilepsy eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in